Thrilled to be at ObesityWeek? to present data on TLC-1180, our potent, long-acting, next-generation mitochondrial protonophore for the treatment of obesity. Kudos to Natalie Sroda, Archana Vijayakumar, and team for this poster showing high in vitro potency and dose-dependent increases in energy expenditure and weight loss in obese mice treated with TLC-1180. Stay tuned for GLP-1 receptor agonist combination data!
OrsoBio
生物技术研究
Palo Alto，CA 2,169 位关注者
Advancing first-in-class therapies to restore energy homeostasis
关于我们
OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.
- 网站
-
www.orsobio.com
OrsoBio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Palo Alto，CA
- 类型
- 私人持股
- 创立
- 2021
地点
-
主要
获取路线
US，CA，Palo Alto
OrsoBio员工
动态
-
We're thrilled to share our recent publication in Journal of Hepatology regarding the potential of ACMSD inhibition in #MASH. In addition to increasing NAD+ levels, TLC-065 enhanced mitochondrial respiration, and decreased DNA damage response, inflammation, and fibrosis in murine and human liver organoid (HLO) models of #MASH. Special thanks to our collaborators Johan Auwerx, Yasmine Liu, Ph.D., and Takanori Takebe for this exciting work! Learn more here: https://bwnews.pr/48oDgld
-
-
OrsoBio is pleased to announce an oversubscribed $67M Series B financing to support advancement of our mitochondrial protonophore portfolio for the treatment of obesity and associated disorders. Special thanks to our new investors, Ascenta Capital and Woodline Partners LP , and to our existing investors, Samsara BioCapital, Longitude Capital, Enavate Sciences, Eli Lilly and Company, and NuevaBio, for their continued support. Read the announcement here: https://bit.ly/3Xye1HY
-
-
OrsoBio is at #ADA2024 and today will present the first of 3 posters describing progress with TLC-6740, our liver-targeted mitochondrial protonophore in development for obesity and associated disorders. Stop by late-breaking poster #1866-LB to learn about our Ph 1 study which demonstrated excellent safety, target engagement and metabolic benefit of TLC-6740 in healthy subjects!
-
Thanks to Brian K. Buntz and Drug Discovery & Development for highlighting our programs and complementarity to #glp1 receptor agonists. https://lnkd.in/gBBEVvrd